Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines
CADTH
Record ID 32012000692
English
Authors' recommendations:
Denosumab and zoledronic acid were shown to be safe and effective in patients with postmenopausal osteoporosis who have switched from oral bisphosphonates, though whether these patients experienced decline or were intolerant of oral bisphosphonate therapy is unclear.
Compliance rates are generally inadequate in patients taking oral bisphosphonates and improved in patients on denosumab therapy. Clinical practice guidelines recommend that zoledronic acid, denosumab, strontium ranelate, or calcitonin be used to treat patients who are intolerant to oral bisphosphonate therapy. No evidence for the cost effectiveness of denosumab or zoledronic acid in patients experiencing decline on oral bisphosphonate treatment was identified.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.cadth.ca/media/pdf/htis/july-2012/RC0366%20Prolia.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antibodies, Monoclonal
- Diphosphonates
- Imidazoles
- Bone Density Conservation Agents
- Cost-Benefit Analysis
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.